Literature DB >> 15466774

Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians.

Vincenza Snow1, Patricia Barry, Stephan D Fihn, Raymond J Gibbons, Douglas K Owens, Sankey V Williams, Christel Mottur-Pilson, Kevin B Weiss.   

Abstract

In 1999, the American College of Physicians (ACP), then the American College of Physicians-American Society of Internal Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) developed joint guidelines on the management of patients with chronic stable angina. The ACC/AHA then published an updated guideline in 2002, which ACP recognized as a scientifically valid review of the evidence and background paper. This ACP guideline summarizes the recommendations of the 2002 ACC/AHA updated guideline and underscores the recommendations most likely to be important to physicians seeing patients in the primary care setting. This guideline is the second of 2 that provide guidance on the management of patients with chronic stable angina. This document covers treatment and follow-up of symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months. Sections addressing asymptomatic patients are also included. Asymptomatic refers to patients with known or suspected coronary disease based on a history or electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests. A previous guideline covered diagnosis and risk stratification for symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months and asymptomatic patients with known or suspected coronary disease based on a history or electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests.

Entities:  

Mesh:

Year:  2004        PMID: 15466774     DOI: 10.7326/0003-4819-141-7-200410050-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

Review 1.  [Blood pressure independent effects of antihypertensive agents].

Authors:  U Wenzel; G Wolf
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

Review 2.  Ranolazine: a review of its use in chronic stable angina pectoris.

Authors:  M Asif A Siddiqui; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.

Authors:  Henry A Tran; Arthur Schwartzbard; Howard S Weintraub
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-08

4.  Long-term medication adherence after myocardial infarction: experience of a community.

Authors:  Nilay D Shah; Shannon M Dunlay; Henry H Ting; Victor M Montori; Randal J Thomas; Amy E Wagie; Véronique L Roger
Journal:  Am J Med       Date:  2009-06-26       Impact factor: 4.965

5.  Challenges and opportunities in the design of age-appropriate drug products.

Authors:  S Stegemann
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

6.  Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-03-01

7.  Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.

Authors:  Cho-Kai Wu; Jen-Kuang Lee; Lian-Yu Lin; Yin-Tsen Huang; Juey-Jen Hwang; Chunn-Lee Lin; Chuen-Den Tseng; Fu-Tien Chiang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

8.  QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology.

Authors:  Meng Li; Yueyao Wang; Zhongwen Qi; Zhuo Yuan; Shichao Lv; Yawei Zheng; Zhipeng Yan; Mingyang Wang; Huanjie Fu; Xinbiao Fan; Nan Ji; Ming Liu; Zhuyuan Fang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.